RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Clinical trials for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hope for Tough-to-Treat blood cancer
Disease control Recruiting nowThis study is testing whether a combination of two new drugs, SHR-0302 and SHR-2554, can help control a rare and aggressive type of blood cancer called peripheral T-cell lymphoma that has come back or hasn't responded to prior treatments. It will enroll about 25 adult patients to…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Fudan University • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC
-
New hope for Tough-to-Treat blood cancer: phase 3 trial tests experimental pill
Disease control Recruiting nowThis study is testing whether an experimental pill called XNW5004 works better than an existing drug (Chidamide) for patients whose peripheral T-cell lymphoma has come back or hasn't responded to prior treatment. It's a Phase 3 trial enrolling 120 adults who have already tried at…
Matched conditions: RELAPSED/REFRACTORY PERIPHERAL T CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Evopoint Biosciences Inc. • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC